Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.

English PA, Williams JA, Martini JF, Motzer RJ, Valota O, Buller RE.

Future Oncol. 2016 Jan;12(2):175-82. doi: 10.2217/fon.15.290. Epub 2015 Dec 17.

2.

BRCA2 alteration is important in clear cell carcinoma of the ovary.

Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE.

Clin Genet. 2009 Aug;76(2):161-7. doi: 10.1111/j.1399-0004.2009.01207.x. Epub 2009 Jul 28.

PMID:
19656163
3.

Tunneled central venous catheters in a gynecologic oncology service: operative and short-term complications.

Geisler JP, Buller RE, Manahan KJ.

Eur J Gynaecol Oncol. 2008;29(2):141-3.

PMID:
18459548
4.

Asymptomatic lung carcinoma presenting with a large vulvar lesion.

Cooper BC, Buekers TE, Flynn CM, Sorosky JI, Buller RE.

J Low Genit Tract Dis. 2001 Jan;5(1):48-50.

PMID:
17043562
5.

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA.

Clin Cancer Res. 2006 Jun 15;12(12):3730-9.

6.

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.

DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA.

Oncogene. 2006 Sep 28;25(44):6026-31. Epub 2006 May 15.

PMID:
16702959
7.

CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.

Kim SC, Ju W, Mahavni V, Geisler JP, Buller RE.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:190-4. Erratum in: Int J Gynecol Cancer. 2006 May-Jun;16(3):1489.

PMID:
16515589
8.

Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration.

Geisler JP, Manahan KJ, Buller RE.

Gynecol Oncol. 2006 Jan;100(1):53-7. Epub 2005 Oct 27.

PMID:
16257042
9.

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE.

Clin Cancer Res. 2005 May 15;11(10):3733-42.

10.

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5.

11.

Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.

Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE.

Cancer. 2003 Nov 15;98(10):2199-206.

12.

Malignant mixed mullerian tumor of the ovary and bilateral breast cancer: an argument for BRCA3, or a coincidental cluster of unconnected cancers?

Burns BA, Geisler JP, Hatterman-Zogg MA, De Young B, Buller RE.

Gynecol Oncol. 2003 Nov;91(2):426-8.

PMID:
14599878
13.

The impact of p53 protein core domain structural alteration on ovarian cancer survival.

Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE.

Clin Cancer Res. 2003 Sep 15;9(11):4139-44.

14.

The influence of microvessel density on ovarian carcinogenesis.

Stone PJ, Goodheart MJ, Rose SL, Smith BJ, DeYoung BR, Buller RE.

Gynecol Oncol. 2003 Sep;90(3):566-71.

PMID:
13678725
15.

Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma.

Bender DP, Sorosky JI, Buller RE, Sood AK.

Am J Obstet Gynecol. 2003 Jul;189(1):113-7.

PMID:
12861147
16.

Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD.

Gynecol Oncol. 2003 May;89(2):267-70.

PMID:
12713990
17.

p21 expression predicts outcome in p53-null ovarian carcinoma.

Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE.

Clin Cancer Res. 2003 Mar;9(3):1028-32.

18.

p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.

Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A.

Cancer Biol Ther. 2002 Sep-Oct;1(5):511-7.

PMID:
12496479
19.

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK.

Clin Cancer Res. 2002 Oct;8(10):3193-7.

20.

Inactivation of BRCA1 and BRCA2 in ovarian cancer.

Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE.

J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406.

PMID:
12237285
21.

Vascular endothelial growth factor and social support in patients with ovarian carcinoma.

Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK.

Cancer. 2002 Aug 15;95(4):808-15.

22.

Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.

Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE.

Obstet Gynecol. 2002 Jul;100(1):59-64.

PMID:
12100804
23.

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.

Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M.

Cancer Gene Ther. 2002 Jul;9(7):567-72.

24.

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.

Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M.

Cancer Gene Ther. 2002 Jul;9(7):553-66.

25.

Ovarian cancer p53 mutation is associated with tumor microvessel density.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE.

Gynecol Oncol. 2002 Jul;86(1):85-90.

PMID:
12079305
26.

The role of p53 mutation in BRCA1-associated ovarian cancer.

Rose SL, Buller RE.

Minerva Ginecol. 2002 Jun;54(3):201-9. Review.

PMID:
12063435
27.

Failure of BRCA1 dysfunction to alter ovarian cancer survival.

Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS.

Clin Cancer Res. 2002 May;8(5):1196-202.

28.

Quality of life and mood in women with gynecologic cancer: a one year prospective study.

Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie J.

Cancer. 2002 Jan 1;94(1):131-40.

29.

Frequency of BRCA1 dysfunction in ovarian cancer.

Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE.

J Natl Cancer Inst. 2002 Jan 2;94(1):61-7.

PMID:
11773283
30.

Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.

Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE.

Gynecol Oncol. 2001 Dec;83(3):501-3.

PMID:
11733962
31.

Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).

Geisler JP, Hatterman-Zogg MA, Rathe JA, Lallas TA, Kirby P, Buller RE.

Hum Mutat. 2001 Oct;18(4):337-44.

PMID:
11668617
32.

Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study.

Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE.

Gynecol Oncol. 2001 Nov;83(2):355-62.

PMID:
11606097
33.

The androgen receptor and DXS15-134 markers show a high rate of discordance for germline X chromosome inactivation.

Mahavni V, Kim SC, Benda TA, Sanders L, Buller RE.

J Med Genet. 2001 Jul;38(7):474-8. No abstract available.

34.
35.

The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.

Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA.

Clin Cancer Res. 2001 Apr;7(4):831-8.

36.

p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.

Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK.

Am J Obstet Gynecol. 2001 Apr;184(5):891-902; discussion 902-3.

PMID:
11303196
37.

Molecular determinants of ovarian cancer plasticity.

Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ.

Am J Pathol. 2001 Apr;158(4):1279-88.

38.

Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.

Bösze P, Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJ, Vermorken JB, Wells M, Wilbanks GD.

Eur J Gynaecol Oncol. 2000;21(5):513-26. Review. No abstract available.

PMID:
11198047
39.

Ovarian function after surgical treatment for cervical cancer.

Buekers TE, Anderson B, Sorosky JI, Buller RE.

Gynecol Oncol. 2001 Jan;80(1):85-8.

PMID:
11136575
40.

SSCP and Sequence Analysis of p53 Mutations in Ovarian Tumors.

Sood AK, Buller RE.

Methods Mol Med. 2001;39:323-8. doi: 10.1385/1-59259-071-3:323.

PMID:
21340787
41.

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.

Shahin MS, Hughes JH, Sood AK, Buller RE.

Cancer. 2000 Nov 1;89(9):2006-17.

PMID:
11064359
42.

Longterm central venous access in gynecologic cancer patients.

Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE.

J Am Coll Surg. 2000 Oct;191(4):403-9.

PMID:
11030246
43.

Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva.

Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RE.

Cancer. 2000 Oct 1;89(7):1520-5.

PMID:
11013366
44.

Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer.

Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI.

Cancer. 2000 Sep 15;89(6):1402-11.

PMID:
11002237
45.

Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.

Sood AK, Sorosky JI, Squatrito RC, Skilling JS, Anderson B, Buller RE.

Neoplasia. 1999 Jun;1(2):118-22.

46.

The glutathione S-transferase M1 genotype in ovarian cancer.

Lallas TA, McClain SK, Shahin MS, Buller RE.

Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):587-90.

47.

Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes.

Sood AK, Sorosky JI, Mayr N, Anderson B, Buller RE, Niebyl J.

Obstet Gynecol. 2000 Jun;95(6 Pt 1):832-8.

PMID:
10831976
48.

Computed tomography in endometrial carcinoma.

Connor JP, Andrews JI, Anderson B, Buller RE.

Obstet Gynecol. 2000 May;95(5):692-6.

PMID:
10775731
49.

Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.

Buekers TE, Lallas TA, Buller RE.

Gynecol Oncol. 2000 Mar;76(3):418-22.

PMID:
10684722
50.

BRCA1: what do we know? What do we think we know? What do we really need to know?

Buller RE.

Gynecol Oncol. 2000 Mar;76(3):291-3. No abstract available.

PMID:
10684698

Supplemental Content

Loading ...
Support Center